STMN1在胶质瘤中表达的临床意义及其与患者替莫唑胺化疗耐药的相关性  

Clinical Significance of STMN1 Expression in Glioma and Its Correlation With Temozolomide Chemotherapy Resistance in Patients

作　　者：陈淑丽[1] 王文节 杜伟[1] 张琳[1] CHEN Shuli;WANG Wenjie;DU Wei(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450000)

机构地区：[1]郑州大学第一附属医院,450000

出　　处：《实用癌症杂志》2025年第1期13-16,33,共5页The Practical Journal of Cancer

基　　金：2020年度河南省医学科技攻关计划省部共建项目(编号:SBGJ202002108)。

摘　　要：目的分析微管解聚蛋白1(STMN1)在胶质瘤中表达的临床意义及其与患者替莫唑胺化疗耐药的相关性。方法收集78例胶质瘤患者临床资料进行研究。依照患者替莫唑胺化疗疗效耐药情况分为耐药组(17例)和非耐药组(61例)。比较2组一般资料、STMN1表达;STMN1与胶质瘤患者耐药因子表达的相关性;二元逻辑回归分析STMN1与胶质瘤患者替莫唑胺化疗耐药的关系;受试者工作特征曲线(ROC)下面积(AUC)评价STMN1对胶质瘤患者替莫唑胺化疗耐药的预测效能。结果2组年龄、体质量指数、性别、肿瘤类型比较,差异无统计学意义(P>0.05)。耐药组STMN1相对蛋白表达量(0.48±0.07)高于非耐药组(0.42±0.05),差异有统计学意义(t=3.991,P=0.000)。P-gP、MGMT阳性患者STMN1水平均高于P-gP、MGMT阴性患者,hMLH、hMSH2阳性患者STMN1水平均低于hMLH、hMSH2阴性患者,差异有统计学意义(P<0.05)。二元逻辑回归分析结果显示,STMN1可能是胶质瘤患者替莫唑胺化疗耐药的独立危险因素(OR>1,β>0,P<0.05),STMN1与胶质瘤患者替莫唑胺化疗耐药呈正相关关系(γ=8.305,P=0.003)。STMN1预测胶质瘤患者替莫唑胺化疗耐药的AUC为0.720,特异度较高,但灵敏度较低。STMN1预测胶质瘤患者替莫唑胺化疗耐药的相对蛋白表达量阈值为0.485。结论STMN1表达在胶质瘤替莫唑胺化疗耐药患者癌组织中异常升高,STMN1可能与替莫唑胺化疗耐药有关,STMN1表达越高,胶质瘤患者替莫唑胺化疗耐药的风险可能越高。Objective To analyze the clinical significance of microtubule depolymerizing protein 1(STMN1)expression in glioma and its correlation with temozolomide chemotherapy resistance in patients.Methods The clinical data of 78 patients with glioma were collected and studied.Patients were divided into drug resistant group(17 cases)and non-drug resistant group(61 cases)according to the efficacy and drug resistance of temozolomide.The general data and STMN1 expression of the 2 groups were compared.Correlation between STMN1 and the expression of drug resistance factors in glioma patients;Binary logistic regression was used to analyze the relationship between STMN1 and temozolomide resistance in glioma patients.The area under receiver Operating characteristic curve(ROC)curve(AUC)was used to evaluate the predictive efficacy of STMN1 in temozolomide resistance in glioma patients.Results There was no significant difference in age,body mass index,sex and tumor type between the two groups(P>0.05).The relative protein expression of STMN1 in drug-resistant group(0.48±0.07)was higher than that in non-drug-resistant group(0.42±0.05),and the difference was statistically significant(t=3.991,P=0.000).STMN1 levels in P-GP and MGMT positive patients were higher than those in P-GP and MGMT negative patients,and STMN1 levels in hMLH and HMSH2-positive patients were lower than those in hMLH and HMSH2-negative patients,the difference was significant(P<0.05).Binary logistic regression analysis showed that STMN1 may be an independent risk factor for temozolomide chemotherapy resistance in glioma patients,with OR value>1,βvalue>0,P value<0.05,and STMN1 was positively correlated with temozolomide chemotherapy resistance in glioma patients(γ=8.305,P=0.003).STMN1 predicted that the AUC of temozolomide resistance in glioma patients was 0.720,with high specificity and low sensitivity.STMN1 predicted that the relative protein expression threshold of temozolomide resistance in glioma patients was 0.485.Conclusion STMN1 expression is abnormally elev

关 键 词：STMN1 胶质瘤 替莫唑胺 化疗 耐药 相关性 

分 类 号：R739.41[医药卫生—肿瘤]